Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases

Int Immunol. 2016 Apr;28(4):181-8. doi: 10.1093/intimm/dxv063. Epub 2015 Nov 6.


Inflammatory cytokines are key regulators of immune responses. Persistent and excessive production of inflammatory cytokines underscores the development of autoimmune diseases. Therefore, neutralizing inflammatory cytokines or antagonizing their receptor function is considered as a useful therapeutic strategy to treat autoimmune diseases. To achieve the success of such a strategy, understanding of the complex actions of these cytokines and cytokine networks is required. In this review we focus on four inflammatory cytokines--tumor necrosis factor α (TNFα), interleukin-6 (IL-6), IL-23 and IL-17--and dissect how the dysregulation of these cytokines regulates autoimmune diseases. On the basis of pre-clinical and clinical data, we specifically discuss the therapeutic rationale for targeting these cytokines and describe the potential adverse effects.

Keywords: IL-17; IL-23; IL-6; TNFα; Th17; autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies / pharmacology*
  • Antibodies / therapeutic use*
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / metabolism*
  • Autoimmune Diseases / therapy
  • Cytokines / antagonists & inhibitors*
  • Cytokines / metabolism*
  • Humans
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / metabolism*
  • Molecular Targeted Therapy


  • Antibodies
  • Cytokines
  • Inflammation Mediators